SPCG17: Prostate Cancer Active Surveillance Trigger Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

October 3, 2016

Primary Completion Date

December 31, 2034

Study Completion Date

December 31, 2034

Conditions
Prostate Cancer
Interventions
PROCEDURE

Active surveillance

Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.

Trial Locations (23)

Unknown

Rigshospitalet, Copenhagen

Odense University Hospital, Odense

Helsinki University Hospital, Helsinki

Seinäjoki Central Hospital, Tampere

Ålesund Regional Hospital, Ålesund

Oslo University Hospital, Oslo

University Hospital of North Norway, Tromsø

St Olavs University Hospital, Trondheim

Hospital of Vestfold, Tønsberg

Sahlgrenska University Hospital, Gothenburg

Linköping University Hospital, Linköping

Sunderby Regional Hospital, Luleå

Örebro University Hospital, Örebro

Sundsvall Regional Hospital, Sundsvall

Umeå University Hospital, Umeå

Akademiska University Hospital, Uppsala

Växjö Hospital, Vaxjo

Bedford Hospital, Bedford

Croydon University Hospital, Croydon

Epsom and St Helier Hospital, London

Guy's Hospital, London

Queen Elisabeth Hospital, London

Royal Marsden Hospital, London

All Listed Sponsors
lead

Uppsala University

OTHER

NCT02914873 - SPCG17: Prostate Cancer Active Surveillance Trigger Trial | Biotech Hunter | Biotech Hunter